First international Competition on Runtime Verification: rules, benchmarks, tools, and final results of CRV 2014

被引：0

作者：

Ezio Bartocci

Yliès Falcone

Borzoo Bonakdarpour

Christian Colombo

Normann Decker

Klaus Havelund

Yogi Joshi

Felix Klaedtke

Reed Milewicz

Giles Reger

Grigore Rosu

Julien Signoles

Daniel Thoma

Eugen Zalinescu

Yi Zhang

机构：

[1] TU Wien,Inria, CNRS, Laboratoire d’Informatique de Grenoble

[2] Univ. Grenoble-Alpes,undefined

[3] University of Illinois at Urbana-Champaign,undefined

[4] McMaster University,undefined

[5] University of Malta,undefined

[6] Lübeck University,undefined

[7] Jet Propulsion Laboratory,undefined

[8] NASA,undefined

[9] University of Waterloo,undefined

[10] NEC Laboratories Europe,undefined

[11] University of Alabama at Birmingham,undefined

[12] University of Manchester,undefined

[13] CEA,undefined

[14] LIST,undefined

[15] Software Security Laboratory,undefined

[16] ETH Zurich,undefined

来源：

International Journal on Software Tools for Technology Transfer | 2019年 / 21卷

关键词：

Runtime Verification; Software competition; Monitoring; Benchmarks;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

The first international Competition on Runtime Verification (CRV) was held in September 2014, in Toronto, Canada, as a satellite event of the 14th international conference on Runtime Verification (RV’14). The event was organized in three tracks: (1) offline monitoring, (2) online monitoring of C programs, and (3) online monitoring of Java programs. In this paper, we report on the phases and rules, a description of the participating teams and their submitted benchmark, the (full) results, as well as the lessons learned from the competition.

引用

页码：31 / 70

页数：39

共 35 条

[21] Predicting resistance to first-line FOLFOX plus bevacizumab in metastatic colorectal cancer: Final results of the multicenter, international PERMAD trial.
Seufferlein, Thomas
Ettrich, Thomas Jens
Stein, Alexander
Arnold, Dirk
Prager, Gerald W.
Kasper, Stefan
Niedermeier, Michael
Muller, Lothar
Kubicka, Stefan
Koenig, Alexander
Buchner-Steudel, Petra
Wille, Kai
Kestler, Angelika M. R.
Berger, Andreas W.
Perkhofer, Lukas
Lausser, Ludwig
Kestler, Hans A.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[22] Chlamydophila Psittaci Eradication With Doxycycline As First-Line Targeted Therapy for Ocular Adnexae Lymphoma: Final Results of an International Phase II Trial
Ferreri, Andres J. M.
Govi, Silvia
Pasini, Elisa
Mappa, Silvia
Bertoni, Francesco
Zaja, Francesco
Montalban, Carlos
Stelitano, Caterina
Elena Cabrera, Maria
Resti, Antonio Giordano
Politi, Letterio Salvatore
Doglioni, Claudio
Cavalli, Franco
Zucca, Emanuele
Ponzoni, Maurilio
Dolcetti, Riccardo
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (24) : 2988 - 2994
[23] CAPECITABINE (CAPE) ± BEVACIZUMAB (BEV) IN THE ADJUVANT TREATMENT OF COLORECTAL CANCER (CRC) FIRST AND FINAL TOXICITY RESULTS FROM THE INTERNATIONAL PHASE III QUASAR2 TRIAL
Midgley, R. S.
Love, S.
Potter, V.
Segelov, E.
Ferry, D. R.
Weaver, A.
Scudder, C.
Julier, P.
Grumett, S.
Kerr, D. J.
ANNALS OF ONCOLOGY, 2012, 23 : 181 - 182
[24] Chlamydophila Psittaci Eradication With Doxycycline As First-Line Targeted Therapy for Ocular Adnexae Lymphoma: Final Results of an International Phase II Trial (vol 30, pg 2988, 2012)
Ferreri
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (31) : 3903 - 3903
[25] Oral Vinorelbine Plus Cisplatin as First-Line Chemotherapy in Nonsquamous Non-Small-Cell Lung Cancer: Final Results of an International Randomized Phase II Study (NAVotrial 01)
Bennouna, Jaafar
Havel, Libor
Krzakowski, Maciej
Kollmeier, Jens
Gervais, Radj
Dansin, Eric
Serke, Monika
Favaretto, Adolfo
Szczesna, Aleksandra
Cobo, Manuel
Ciuffreda, Libero
Jassem, Jacek
Nicolini, Mario
Ramlau, Rodryg
Amoroso, Domenico
Melotti, Barbara
Almodovar, Teresa
Riggi, Marcello
Caux, Noel-Raphael
Vaissiere, Nathalie
Tan, Eng-Huat
CLINICAL LUNG CANCER, 2014, 15 (04) : 258 - 265
[26] International randomised phase III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) in first line treatment of metastatic colorectal cancer (mCRC): final results of the AGITG MAX trial
Tebbutt, N.
Gebski, V.
Wilson, K.
Cummins, M.
Robinson, B.
Broad, A.
Cunningham, D.
Simes, J.
Stockler, M.
Price, T.
EJC SUPPLEMENTS, 2009, 7 (02): : 321 - 321
[27] CHLAMYDOPHILA PSITTACI ERADICATION WITH DOXYCYCLINE IS AN ACTIVE FIRST-LINE TARGETED THERAPY FOR OCULAR ADNEXAE LYMPHOMA: FINAL RESULTS OF AN INTERNATIONAL PHASE II PROSPECTIVE STUDY ((IELSG#27 TRIAL)
Govi, S.
Pasini, E.
Mappa, S.
Bertoni, F.
Zaja, F.
Montalban, C.
Stelitano, C.
Cabrera, M. E.
Resti, A.
Politi, L.
Doglioni, C.
Cavalli, F.
Zucca, E.
Spagnuolo, L.
Ponzoni, M.
Dolcetti, R.
Ferreri, A.
HAEMATOLOGICA, 2012, 97 : 459 - 459
[28] International randomized phase III study of capecitabine (Cap), bevacizumab (Bev), and mitomycin C (MMC) in first-line metastatic colorectal cancer (mCRC): Final results of the AGITG MAX trial
Tebbutt, N. C.
Gebski, V.
Wilson, K.
Cummins, M.
Chua, Y.
Robinson, B.
Broad, A.
Cunningham, D.
Simes, J.
Price, T.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[29] Growth hormone treatment of short children born small for gestational age or with Silver-Russell syndrome: Results from KIGS (Kabi International Growth Study), including the first report on final height
Ranke, MB
Lindberg, A
ACTA PAEDIATRICA, 1996, 85 : 18 - 26
[30] First-Line Treatment for Primary Testicular Diffuse Large B-Cell Lymphoma With Rituximab-CHOP, CNS Prophylaxis, and Contralateral Testis Irradiation: Final Results of an International Phase II Trial
Vitolo, Umberto
Chiappella, Annalisa
Ferreri, Andres J. M.
Martelli, Maurizio
Baldi, Ileana
Balzarotti, Monica
Bottelli, Chiara
Conconi, Annarita
Gomez, Henry
Lopez-Guillermo, Armando
Martinelli, Giovanni
Merli, Francesco
Novero, Domenico
Orsucci, Lorella
Pavone, Vincenzo
Ricardi, Umberto
Storti, Sergio
Gospodarowicz, Mary K.
Cavalli, Franco
Sarris, Andreas H.
Zucca, Emanuele
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (20) : 2766 - 2772

← 1 2 3 4 →